All Institutions
Search all resources
Search for entire words only

DOT-Cells® - a novel, safe, cellular immunotherapy for Chronic Lymphocytic Leukaemia

Lymphact S.A.
Project classification

Scientific area

3.2 Clinical medicine



Project description

Project title

DOT-Cells® - a novel, safe, cellular immunotherapy for Chronic Lymphocytic Leukaemia

Scientific Coordinator's name:

Bruno Silva-Santos

Scientific Coordinator's e-mail:

Principal R&D Unit:

Lymphact R&D

Other R&D Units involved in the project:


Project keyword(s)

Immunotherapy, CLL, Cell therapy, Biotechnology, Immunology, oncology, haematology

Short abstract and comments

After 5 years of pioneering research and development in this field, we created a new technology platform that can generate autologous and allogeneic cellular immune therapies for clinical applications. Our solution can target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, believed to cause disease recurrence. An improved anti-tumour function and the absence of severe associated side-effects are distinctive and unique features of our therapeutic approach. Our first product, DOT-cells®, is an autologous adoptive immunotherapy designed to treat a wide range of malignancies with unmet medical needs. A primary application on relapsed and refractory chronic lymphocytic leukaemia (CLL) patients will be the first product of our pipeline. We will finish all the necessary pre-clinical studies in about 3 months. We plan to obtain orphan drug status from the EMA and then proceed to phase I clinical trials. Scheduled to start in mid-2015, these clinical studies will allow our promising therapeutical approach to reach the patient and the market, paving the way for Lymphact.

Potential uses/indications

Refractory/relapsed Chronic Lymphocytic Leukaemia; CLL patients with one or more of the following: advanced age; comorbidity; TP53 mutation; 17p deletion.



Partner Status: Seeking Partners?


Project weblink

Grant number (QREN, FP7, Eureka, etc)


Last edited on

2014-11-10 16:47:30

Health Cluster Portugal All rights reserved
© 2024 Health Cluster Portugal All rights reserved